Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
P/E ratio for Entrada Therapeutics, Inc. (TRDA)
P/E ratio as of 2023: -74.60
According to Entrada Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -74.60. At the end of 2022 the company had a P/E ratio of -4.84.
P/E ratio history for Entrada Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -74.60 |
| 2022 | -4.84 |
| 2021 | -10.68 |
| 2020 | -28.37 |
| 2019 | -160.98 |